Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma
- 1 June 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16), 3871-3872
- https://doi.org/10.1200/jco.2005.55.250
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- CXCR4 Regulates Migration and Development of Human Acute Myelogenous Leukemia Stem Cells in Transplanted NOD/SCID MiceCancer Research, 2004
- Unique SDF-1–induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signalingBlood, 2004
- Rapid Mobilization of CD34+ Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2004
- CCL19 and CXCL12 Triggerin VitroChemotaxis of Human Mantle Cell Lymphoma B CellsClinical Cancer Research, 2004
- Mobilization of Myeloma Cells Involves SDF‐1/CXCR4 Signaling and Downregulation of VLA‐4The International Journal of Cell Cloning, 2004
- Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cellsOncogene, 2003
- CXCR4–SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesionBlood, 2002
- Involvement of chemokine receptors in breast cancer metastasisNature, 2001
- Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular LymphomaBlood, 1999
- Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic CellsJournal of Clinical Oncology, 1999